{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:41:07Z","timestamp":1792431667512,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":55,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.josat.2026.209994","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:22:02Z","timestamp":1777011722000},"page":"209994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["National Institute on Drug Abuse (NIDA) clinical trials network (CTN) stimulant use disorder (StUD) task force results: 2024 update"],"prefix":"10.1016","author":[{"given":"Chatnapha","family":"Kittirattanapaiboon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Shoptaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn L.","family":"Mayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish K.","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udi E.","family":"Ghitza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhukar H.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2026.209994_bb0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neubiorev.2020.03.017","article-title":"Long-term effects of psychedelic drugs: A systematic review","volume":"113","author":"Aday","year":"2020","journal-title":"Neuroscience & Biobehavioral Reviews"},{"key":"10.1016\/j.josat.2026.209994_bb0010","doi-asserted-by":"crossref","first-page":"108614","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"16","key":"10.1016\/j.josat.2026.209994_bb0015","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1007\/s00213-017-4632-7","article-title":"Role of the agranular insular cortex in contextual control over cocaine-seeking behavior in rats","volume":"234","author":"Arguello","year":"2017","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.josat.2026.209994_bb0020","first-page":"45","article-title":"Guanfacine for the treatment of cognitive disorders: A century of discoveries at Yale","volume":"85","author":"Arnsten","year":"2012","journal-title":"The Yale Journal of Biology and Medicine"},{"key":"10.1016\/j.josat.2026.209994_bb0025","doi-asserted-by":"crossref","first-page":"112116","DOI":"10.1016\/j.pscychresns.2025.112116","article-title":"Distinct subcortical connectivity patterns of opioid and stimulant use disorders: A resting-state fMRI study","volume":"357","author":"Atanasova","year":"2026","journal-title":"Psychiatry Research: Neuroimaging"},{"key":"10.1016\/j.josat.2026.209994_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"11","key":"10.1016\/j.josat.2026.209994_bb0035","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrn3104","article-title":"Opiate versus psychostimulant addiction: The differences do matter","volume":"12","author":"Badiani","year":"2011","journal-title":"Nature Reviews. Neuroscience"},{"issue":"3","key":"10.1016\/j.josat.2026.209994_bb0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/0269881114565144","article-title":"Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study","volume":"29","author":"Bogenschutz","year":"2015","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.josat.2026.209994_bb0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/bs.pbr.2017.08.002","article-title":"Using the research domain criteria (RDoC) to conceptualize impulsivity and compulsivity in relation to addiction","volume":"235","author":"Brooks","year":"2017","journal-title":"Progress in Brain Research"},{"key":"10.1016\/j.josat.2026.209994_bb0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.physbeh.2019.03.029","article-title":"The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: A systematic review","volume":"206","author":"Brunchmann","year":"2019","journal-title":"Physiology & Behavior"},{"issue":"2","key":"10.1016\/j.josat.2026.209994_bb0055","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamapsychiatry.2025.2864","article-title":"Stimulant use disorder diagnoses in adolescent and young adult medicaid enrollees","volume":"83","author":"Bushnell","year":"2026","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"10.1016\/j.josat.2026.209994_bb0060","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14728214.2017.1395855","article-title":"Medications for substance use disorders (SUD): Emerging approaches","volume":"22","author":"Butelman","year":"2017","journal-title":"Expert Opinion on Emerging Drugs"},{"issue":"2","key":"10.1016\/j.josat.2026.209994_bb0065","doi-asserted-by":"crossref","first-page":"8","DOI":"10.64719\/pb.4485","article-title":"Clavulanic acid decreases cocaine cue reactivity in addiction-related brain areas, a randomized fMRI pilot study","volume":"54","author":"Callans","year":"2024","journal-title":"Psychopharmacology Bulletin"},{"issue":"12","key":"10.1016\/j.josat.2026.209994_bb0070","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1089\/pho.2018.4490","article-title":"Transcranial photobiomodulation for the treatment of major depressive disorder. The ELATED-2 pilot trial","volume":"36","author":"Cassano","year":"2018","journal-title":"Photomedicine and Laser Surgery"},{"issue":"3","key":"10.1016\/j.josat.2026.209994_bb0075","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","article-title":"Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: A placebo-controlled randomized clinical trial","volume":"77","author":"Coffin","year":"2020","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.josat.2026.209994_bb0080","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archgenpsychiatry.2011.124","article-title":"Mirtazapine to reduce methamphetamine use: A randomized controlled trial","volume":"68","author":"Colfax","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1016\/j.josat.2026.209994_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.724606","article-title":"Psychedelics and neuroplasticity: A systematic review unraveling the biological underpinnings of psychedelics","volume":"12","author":"de Vos","year":"2021","journal-title":"Frontiers in Psychiatry"},{"issue":"1","key":"10.1016\/j.josat.2026.209994_bb0090","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41386-024-01941-z","article-title":"The promise of precision functional mapping for neuroimaging in psychiatry","volume":"50","author":"Demeter","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.josat.2026.209994_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061724","article-title":"Photobiomodulation-underlying mechanism and clinical applications","volume":"9","author":"Dompe","year":"2020","journal-title":"Journal of Clinical Medicine"},{"issue":"12","key":"10.1016\/j.josat.2026.209994_bb0100","doi-asserted-by":"crossref","first-page":"e2548809","DOI":"10.1001\/jamanetworkopen.2025.48809","article-title":"Cue-elicited brain activity and treatment outcomes in substance use disorders: A meta-analysis","volume":"8","author":"Evohr","year":"2025","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2026.209994_bb0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.physbeh.2017.03.019","article-title":"Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core","volume":"176","author":"Fortin","year":"2017","journal-title":"Physiology & Behavior"},{"issue":"7","key":"10.1016\/j.josat.2026.209994_bb0110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1177\/0269881111430746","article-title":"Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: Preliminary findings","volume":"26","author":"Fox","year":"2012","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1016\/j.josat.2026.209994_bb0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1176\/appi.ajp.20230914","article-title":"Primum non nocere: The onus to characterize the potential harms of psychedelic treatment","volume":"182","author":"Ghaznavi","year":"2025","journal-title":"The American Journal of Psychiatry"},{"key":"10.1016\/j.josat.2026.209994_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi4505","article-title":"Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial","volume":"17","author":"Gomez-Mancilla","year":"2025","journal-title":"Science Translational Medicine"},{"issue":"12","key":"10.1016\/j.josat.2026.209994_bb0125","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"Journal of Psychopharmacology"},{"issue":"12","key":"10.1016\/j.josat.2026.209994_bb0130","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.josat.2026.209994_bb0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-007-1020-8","article-title":"Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse","volume":"197","author":"Haney","year":"2008","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.josat.2026.209994_bb0140","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/adb.12621","article-title":"Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers","volume":"24","author":"Haney","year":"2019","journal-title":"Addiction Biology"},{"issue":"1","key":"10.1016\/j.josat.2026.209994_bb0145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12888-025-06555-3","article-title":"The effectiveness of transcranial Photobiomodulation therapy (tPBM) on reducing anxiety, depression, and opioid craving in patients undergoing methadone maintenance treatment: A double-blind, randomized, controlled trial","volume":"25","author":"Helali","year":"2025","journal-title":"BMC Psychiatry"},{"issue":"10","key":"10.1016\/j.josat.2026.209994_bb0150","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.josat.2026.209994_bb0155","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ajad.12959","article-title":"Use of guanfacine for cannabis use disorder and related symptomology","volume":"28","author":"Holst","year":"2019","journal-title":"The American Journal on Addictions"},{"issue":"11","key":"10.1016\/j.josat.2026.209994_bb0160","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1176\/appi.ajp.2019.18101191","article-title":"Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial","volume":"176","author":"Hurd","year":"2019","journal-title":"The American Journal of Psychiatry"},{"issue":"4","key":"10.1016\/j.josat.2026.209994_bb0165","article-title":"Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: A phase 3 randomized clinical trial (GEMINI)","volume":"83","author":"Iosiescu","year":"2022","journal-title":"Journal of Clinical Psychiatry"},{"issue":"11","key":"10.1016\/j.josat.2026.209994_bb0170","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"Journal of Psychopharmacology"},{"issue":"1S Suppl 1","key":"10.1016\/j.josat.2026.209994_bb0175","first-page":"1","article-title":"The ASAM\/AAAP clinical practice guideline on the management of stimulant use disorder","volume":"18","year":"2024","journal-title":"Journal of Addiction Medicine"},{"issue":"3","key":"10.1016\/j.josat.2026.209994_bb0180","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00726-015-2117-8","article-title":"Clavulanic acid enhances glutamate transporter subtype I (GLT-1) expression and decreases reinforcing efficacy of cocaine in mice","volume":"48","author":"Kim","year":"2016","journal-title":"Amino Acids"},{"issue":"4","key":"10.1016\/j.josat.2026.209994_bb0185","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"British Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.josat.2026.209994_bb0190","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0924-9338(00)00219-4","article-title":"Dopamine D\u2083 receptor agents as potential new medications for drug addiction","volume":"15","author":"Le Foll","year":"2000","journal-title":"European Psychiatry"},{"key":"10.1016\/j.josat.2026.209994_bb0195","doi-asserted-by":"crossref","first-page":"107700","DOI":"10.1016\/j.drugalcdep.2019.107700","article-title":"Extended release mixed amphetamine salts and topiramate for cocaine dependence: A randomized clinical replication trial with frequent users","volume":"206","author":"Levin","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.josat.2026.209994_bb0200","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/add.16093","article-title":"Clinical management of psychostimulant withdrawal: Review of the evidence","volume":"118","author":"Li","year":"2023","journal-title":"Addiction"},{"issue":"1\u20132","key":"10.1016\/j.josat.2026.209994_bb0205","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0091-3057(01)00514-7","article-title":"Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine","volume":"69","author":"Lichtman","year":"2001","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"8030","key":"10.1016\/j.josat.2026.209994_bb0210","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-024-07805-2","article-title":"Frontostriatal salience network expansion in individuals in depression","volume":"633","author":"Lynch","year":"2024","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.josat.2026.209994_bb0215","doi-asserted-by":"crossref","first-page":"e70991","DOI":"10.1002\/brb3.70991","article-title":"Craving prediction from fMRI drug cue reactivity in methamphetamine use disorder: A parsimonious neurobiological model","volume":"15","author":"Mahdavi-Doost","year":"2025","journal-title":"Brain and Behavior: A Cognitive Neuroscience Perspective"},{"issue":"11","key":"10.1016\/j.josat.2026.209994_bb0220","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.biopsych.2023.06.031","article-title":"Low-intensity focused ultrasound targeting the bilateral nucleus accumbens as a potential treatment for substance use disorder: A first-in-human report","volume":"94","author":"Mahoney","year":"2023","journal-title":"Biological Psychiatry"},{"issue":"11","key":"10.1016\/j.josat.2026.209994_bb0225","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.biopsych.2012.05.032","article-title":"Extended-release mixed amphetamine salts and topiramate for cocaine dependence: A randomized controlled trial","volume":"72","author":"Mariani","year":"2012","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.josat.2026.209994_bb0230","doi-asserted-by":"crossref","first-page":"100751","DOI":"10.1016\/j.curtheres.2024.100751","article-title":"Clavulanic acid-mediated increases in anterior cingulate glutamate levels are associated with decreased cocaine craving and brain network functional connectivity changes","volume":"101","author":"Maser","year":"2024","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"1","key":"10.1016\/j.josat.2026.209994_bb0235","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1176\/appi.neuropsych.16120328","article-title":"Guanfacine attenuates adverse effects of dronabinol (THC) on working memory in adolescent-onset heavy cannabis users: A pilot study","volume":"30","author":"Mathai","year":"2018","journal-title":"The Journal of Neuropsychiatry and Clinical Neurosciences"},{"issue":"5","key":"10.1016\/j.josat.2026.209994_bb0240","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1590\/1516-4446-2020-1416","article-title":"Cannabidiol for the treatment of crack-cocaine craving: An exploratory double-blind study","volume":"43","author":"Meneses-Gaya","year":"2021","journal-title":"Brazilian Journal of Psychiatry"},{"issue":"9","key":"10.1016\/j.josat.2026.209994_bb0245","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1111\/add.15417","article-title":"Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: A randomized placebo-controlled trial","volume":"116","author":"Mongeau-P\u00e9russe","year":"2021","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2026.209994_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107078","article-title":"IUPHAR review: New strategies for medications to treat substance use disorders","volume":"200","author":"Montoya","year":"2024","journal-title":"Pharmacological Research"},{"issue":"5811","key":"10.1016\/j.josat.2026.209994_bb0255","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1126\/science.1135926","article-title":"Damage to the insula disrupts addiction to cigarette smoking","volume":"315","author":"Naqvi","year":"2007","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.josat.2026.209994_bb0260","doi-asserted-by":"crossref","first-page":"e13150","DOI":"10.1111\/adb.13150","article-title":"CBD-mediated regulation of heroin withdrawal-induced behavioural and molecular changes in mice","volume":"27","author":"Navarrete","year":"2022","journal-title":"Addiction Biology"},{"key":"10.1016\/j.josat.2026.209994_bb0265","doi-asserted-by":"crossref","first-page":"1466506","DOI":"10.3389\/fpsyt.2024.1466506","article-title":"The therapeutic potential of low-intensity focused ultrasound for treating substance use disorder","volume":"15","author":"Olaitan","year":"2024","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.josat.2026.209994_bb0270","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fpsyt.2017.00240","article-title":"The \u201cendless trip\u201d among the NPS users: Psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. A systematic review","volume":"8","author":"Orsolini","year":"2017","journal-title":"Frontiers in Psychiatry"},{"issue":"11","key":"10.1016\/j.josat.2026.209994_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/ph17111464","article-title":"Cariprazine in bipolar disorder and substance use: A dual approach to treatment?","volume":"17","author":"Pardossi","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.josat.2026.209994_bb0280","doi-asserted-by":"crossref","first-page":"100671","DOI":"10.1016\/j.abrep.2026.100671","article-title":"Glucagon-like peptide 1 receptor agonists in substance use disorders: A systematic review of ClinicalTrials.Gov","volume":"23","author":"Patil","year":"2026","journal-title":"Addictive Behaviors Reports"},{"key":"10.1016\/j.josat.2026.209994_bb0285","doi-asserted-by":"crossref","first-page":"107360","DOI":"10.1016\/j.addbeh.2022.107360","article-title":"Cannabidiol in the context of substance use disorder treatment: A systematic review","volume":"132","author":"Paulus","year":"2022","journal-title":"Addictive Behaviors"},{"issue":"47","key":"10.1016\/j.josat.2026.209994_bb0290","doi-asserted-by":"crossref","first-page":"14764","DOI":"10.1523\/JNEUROSCI.4291-09.2009","article-title":"Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances","volume":"29","author":"Ren","year":"2009","journal-title":"The Journal of Neuroscience"},{"issue":"4","key":"10.1016\/j.josat.2026.209994_bb0295","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1001\/jamapsychiatry.2023.5483","article-title":"Parameter space and potential for biomarker development in 25 years of fMRI drug cue reactivity: A systematic review","volume":"81","author":"Sangchooli","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.josat.2026.209994_bb0300","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-011-2343-z","article-title":"Occupancy of dopamine D\u2082 and D\u2083 and serotonin 5-HT\u2081A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography","volume":"218","author":"Seneca","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.josat.2026.209994_bb0305","series-title":"Opioid Withdrawal. [Updated 2023 Jul 21]. StatPearls [Internet]","author":"Shah","year":"2023"},{"key":"10.1016\/j.josat.2026.209994_bb0310","doi-asserted-by":"crossref","first-page":"146164","DOI":"10.1016\/j.brainres.2019.02.026","article-title":"Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin\/orexin transmission and therapeutic prospect","volume":"1731","author":"Simmons","year":"2020","journal-title":"Brain Research"},{"issue":"1","key":"10.1016\/j.josat.2026.209994_bb0315","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41398-023-02565-5","article-title":"Closing the loop between brain and electrical stimulation: Towards precision neuromodulation treatments","volume":"13","author":"Soleimani","year":"2023","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.josat.2026.209994_bb0320","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.neuropharm.2013.04.042","article-title":"Dopamine D(3) receptor deletion or blockade attenuates cocaine-induced conditioned place preference in mice","volume":"72","author":"Song","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.josat.2026.209994_bb0325","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiology & Behavior"},{"key":"10.1016\/j.josat.2026.209994_bb0330","doi-asserted-by":"crossref","first-page":"173466","DOI":"10.1016\/j.pbb.2022.173466","article-title":"Suvorexant maintenance enhances the reinforcing but not subjective and physiological effects of intravenous cocaine in humans","volume":"220","author":"Stoops","year":"2022","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"3","key":"10.1016\/j.josat.2026.209994_bb0335","doi-asserted-by":"crossref","first-page":"499","DOI":"10.2147\/NDT.S1711","article-title":"Once-daily treatment of ADHD with guanfacine: Patient implications","volume":"4","author":"Strange","year":"2008","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"5","key":"10.1016\/j.josat.2026.209994_bb0340","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/FBP.0000000000000731","article-title":"Use of drug purchase tasks in medications development research: Orexin system regulation of cocaine and drug demand","volume":"34","author":"Strickland","year":"2023","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.josat.2026.209994_bb0345","series-title":"Key substance use and mental health indicators in the United States: Results from the 2024 National Survey on Drug Use and Health in NSDUH Series H-60","author":"Substance Abuse and Mental Health Services Administration","year":"2025"},{"key":"10.1016\/j.josat.2026.209994_bb0350","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","article-title":"Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: A randomized double-blind controlled trial","volume":"179","author":"Tabuteau","year":"2022","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.josat.2026.209994_bb0355","doi-asserted-by":"crossref","first-page":"491","DOI":"10.15585\/mmwr.mm7432a1","article-title":"Drug overdose deaths involving stimulants \u2015 United States, January 2018\u2013June 2024","volume":"74","author":"Tanz","year":"2025","journal-title":"MMWR. Morbidity and Mortality Weekly Report"},{"issue":"11","key":"10.1016\/j.josat.2026.209994_bb0360","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s40263-018-0578-5","article-title":"A phase I, randomized, double-blind, placebo-controlled, single ascending dose, multiple dose, and food effect trial of the safety, tolerability and pharmacokinetics of highly purified cannabidiol in healthy subjects","volume":"32","author":"Taylor","year":"2018","journal-title":"CNS Drugs"},{"issue":"Pt A","key":"10.1016\/j.josat.2026.209994_bb0365","doi-asserted-by":"crossref","first-page":"106938","DOI":"10.1016\/j.yebeh.2020.106938","article-title":"Abrupt withdrawal of cannabidiol (CBD): A randomized trial","volume":"104","author":"Taylor","year":"2020","journal-title":"Epilepsy & Behavior"},{"issue":"2","key":"10.1016\/j.josat.2026.209994_bb0370","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa2020214","article-title":"Bupropion and naltrexone in methamphetamine use disorder","volume":"384","author":"Trivedi","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.josat.2026.209994_bb0375","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ajad.13241","article-title":"Case series: Cariprazine for treatment of methamphetamine use disorder","volume":"31","author":"Truong","year":"2022","journal-title":"The American Journal on Addictions"},{"key":"10.1016\/j.josat.2026.209994_bb0380","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1007\/s00213-024-06634-5","article-title":"The mGlu5 receptor negative allosteric modulator mavoglurant reduces escalated cocaine self-administration in male and female rats","volume":"241","author":"Vendruscolo","year":"2024","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.josat.2026.209994_bb0385","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/adb.12495","article-title":"Cannabidiol reduces ethanol consumption, motivation and relapse in mice","volume":"23","author":"Viudez-Mart\u00ednez","year":"2018","journal-title":"Addiction Biology"},{"key":"10.1016\/j.josat.2026.209994_bb0390","first-page":"1","article-title":"Preliminary examination of orexin receptor antagonism with suvorexant in individuals with methamphetamine use disorder: A case series study","author":"Webber","year":"2024","journal-title":"Journal of Addictive Diseases"},{"issue":"2","key":"10.1016\/j.josat.2026.209994_bb0395","doi-asserted-by":"crossref","first-page":"e14330","DOI":"10.1111\/jsr.14330","article-title":"Objective and subjective measurement of sleep in people who use substances: Emerging evidence and recommendations from a systematic review","volume":"34","author":"Webber","year":"2025","journal-title":"Journal of Sleep Research"},{"issue":"4","key":"10.1016\/j.josat.2026.209994_bb0400","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ADM.0000000000001147","article-title":"Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: A case series study","volume":"17","author":"Yammine","year":"2023","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.josat.2026.209994_bb0405","doi-asserted-by":"crossref","first-page":"115886","DOI":"10.1016\/j.psychres.2024.115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis","volume":"335","author":"Yao","year":"2024","journal-title":"Psychiatry Research"},{"key":"10.1016\/j.josat.2026.209994_bb0410","doi-asserted-by":"crossref","first-page":"108719","DOI":"10.1016\/j.drugalcdep.2021.108719","article-title":"Age-specific treatment effects of orexin\/hypocretin-receptor antagonism on methamphetamine-seeking behavior","volume":"224","author":"Zlebnik","year":"2021","journal-title":"Drug and Alcohol Dependence"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926001141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875926001141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:47:15Z","timestamp":1783172835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875926001141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":82,"alternative-id":["S2949875926001141"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2026.209994","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National Institute on Drug Abuse (NIDA) clinical trials network (CTN) stimulant use disorder (StUD) task force results: 2024 update","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2026.209994","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"209994"}}